Fesoterodine (INN, brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome. It was approved by the European Medicines Agency in April 2007 and was approved by the US Food and Drug Administration on October 31, 2008. Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.

PropertyValue
dbpedia-owl:Drug/atcPrefix
  • G04
dbpedia-owl:Drug/atcSuffix
  • BD11
dbpedia-owl:Drug/casNumber
  • 286930-03-8
dbpedia-owl:Drug/iupacName
  • [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
dbpedia-owl:Drug/pubchem
  • 6918558
dbpedia-owl:atcPrefix
  • G04
dbpedia-owl:atcSuffix
  • BD11
dbpedia-owl:casNumber
  • 286930-03-8
dbpedia-owl:iupacName
  • [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
dbpedia-owl:pubchem
  • 6918558
dbpedia-owl:thumbnail
dbpprop:abstract
  • Fesoterodine (INN, brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome. It was approved by the European Medicines Agency in April 2007 and was approved by the US Food and Drug Administration on October 31, 2008. Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.
  • Фезотеродин (англоязычное - Fesoterodine) (Международное непатентованное название, торговая марка Toviaz) - антагонист мускариновых рецепторов, разработанный фирмой Schwarz Pharma AG в качестве лекарственного препарата для лечения синдрома гиперактивного мочевого пузыря. Эффективность фезотеродина была показана в слепых рандомизированных контролируемых исследованиях в сравнении с плацебо и с толтерадином. Европейское медицинское агентство в апреле 2007 года одобрило использование фезотеродина в клинике..
dbpprop:atcPrefix
  • G04
dbpprop:atcSuffix
  • BD11
dbpprop:bioavailability
  • 52% (active metabolite)
dbpprop:c
  • 26 (xsd:integer)
dbpprop:casNumber
  • 286930-03-8
dbpprop:eliminationHalfLife
  • 7–8 hours (active metabolite)
dbpprop:excretion
  • Renal (70%) and fecal (7%)
dbpprop:h
  • 37 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:iupacName
  • [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
dbpprop:legalStatus
  • Rx-only
dbpprop:licenceEu
  • Toviaz
dbpprop:licenceUs
  • Fesoterodine
dbpprop:metabolism
dbpprop:molecularWeight
  • 411.278 g/mol
dbpprop:n
  • 1 (xsd:integer)
dbpprop:o
  • 3 (xsd:integer)
dbpprop:pregnancyUs
  • C
dbpprop:proteinBound
  • 50% (active metabolite)
dbpprop:pubchem
  • 6918558 (xsd:integer)
dbpprop:routesOfAdministration
  • Oral
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Fesoterodine (INN, brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome. It was approved by the European Medicines Agency in April 2007 and was approved by the US Food and Drug Administration on October 31, 2008. Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.
  • Фезотеродин (англоязычное - Fesoterodine) (Международное непатентованное название, торговая марка Toviaz) - антагонист мускариновых рецепторов, разработанный фирмой Schwarz Pharma AG в качестве лекарственного препарата для лечения синдрома гиперактивного мочевого пузыря.
rdfs:label
  • Fesoterodine
  • Фезотеродин
owl:sameAs
skos:subject
foaf:depiction
foaf:page
is dbpprop:redirect of
is owl:sameAs of